Trevena

Go or no go? Valuable drugs set for FDA decisions

Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.

November 05, 2018

US regulator sails into treacherous opioid waters

Public criticism fails to derail approval of Acelrx’s opioid painkiller, but not without a lengthy apologia from Scott Gottlieb.

October 31, 2018

Go or no go? Big decisions for Acelrx, Trevena, Loxo and Astellas

Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.

July 10, 2017

Strong small cap performance drives second-quarter gains

February 24, 2017

Snippet roundup: Cyclacel’s data dredge and Bristol’s activist investor

February 24, 2017

Snippet roundup: Cyclacel’s data dredge and Bristol’s activist investor

January 27, 2017

Upcoming events – Late-stage data from Trevena and Chimerix

May 26, 2016

Innocoll sponges up goodwill after pain success

May 17, 2016

Setbacks still outweigh successes in heart failure

May 17, 2016

Setbacks still outweigh successes in heart failure

May 13, 2016

Safety worries loom for Bayer’s Adempas

Load More